DRP Patent Granted

Allarity Therapeutics, Inc. (NASDAQ: ALLR) has announced that the Japan Patent Office has granted a key patent covering its proprietary stenoparib-specific Drug Response Predictor (DRP) companion diagnostic. The patent, Japanese Patent No. 7917283, provides protection in Japan into 2039. This development is significant as it secures patent protection for the DRP methods used to predict clinical benefit from stenoparib in Japan.